Safe Technologies Licenses Nasal Aspirin Product To Chinese Manufacturer

Safe Technologies International, Inc. (Palm Beach, FL) has entered into a license agreement with the Chinese pharmaceutical company, Hangzhou Jiuyuan Gene Engineering Co., for the production and distribution of its Nasal Aspirin patent. Safe Technologies' patent relates to a novel method of administering aspirin to achieve improved delivery, via nasal administration. Nasal aspirin is particularly effective in the treatment of migraine, cardiovascular damage resulting from heart attack, and acute pain, such as post-operative pain.

Located in the state-grade Hangzhou Economic & Technological Development Zone, Hangzhou Jiuyuan operates a modern facility, specializing in the research, development, production and marketing of pharmaceuticals based on gene-engineering and biochemical technologies. The company's extensive research facility is staffed and co-established with Beijing University and Jiuyuan and Zhejiang University and has the ability to organize preclinical and clinical trials and file new drug applications.

"We are very pleased to license our Nasal Aspirin Patent, with such a prestigious research and development institute as Hangzhou Jiuyuan," said Barbara Tolley, Safe Technologies' CEO. "The Agreement provides Safe Technology International a most unique opportunity for bringing the product to market. We are very aware of the huge market potential for pharmaceutical products in the China market, a potential of over One Billion people. This market will be larger than the European market, in its entirety, by the Year 2000," Tolley concluded.

For more information: Brad Tolley, VP Investor Relations, Safe Technologies International, Inc. Telephone: 561-832-2700.